Kiniksa Pharmaceuticals reported second quarter 2025 ARCALYST net product revenue of $156.8 million, representing a 52% increase year-over-year. This robust commercial performance was driven by expanding ARCALYST penetration across the recurrent pericarditis population, supported by growth among both new and repeat prescribers.
The company raised its full-year 2025 ARCALYST net sales guidance for the second time this year, now expecting sales to be between $625 million and $640 million. This updated guidance reflects 52% year-over-year growth at the midpoint, highlighting the ongoing strength of ARCALYST's commercialization.
Kiniksa announced the initiation of the Phase 2 dose-focusing portion of the pivotal Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis. Data from this part of the study are expected in the second half of 2026, with potential market entry for KPL-387 projected in the 2028/2029 timeframe.
The company's cash balance increased by $39.4 million in the second quarter of 2025, reaching $307.8 million as of June 30, 2025. Kiniksa continues to expect its current operating plan to remain cash flow positive on an annual basis.
KPL-387 is being developed with a target profile of monthly subcutaneous dosing in a liquid formulation, aiming to expand treatment options for recurrent pericarditis patients. Kiniksa also continues IND-enabling activities for KPL-1161, a pre-clinical asset targeting quarterly subcutaneous dosing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.